Avid Bioservices Inc (CDMO)

[PGG76109]

Oops was beaten to it!

Research and Markets: Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
2 Hours AgoBusiness Wire











COMMENTSStart the Discussion

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/rp9tdm/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering.

During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m.

Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market.

In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment.

The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials.

The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline.

Scope

A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis
In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target
Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate
Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
Discussion of the drivers of and barriers to market growth
Discussion of the licensing and co-development deals landscape in GBM

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Marketed drugs

Temodar (temozolomide) - Merck
Avastin (bevacizumab) - Roche
BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
BiCNU (carmustine) - Bristol-Myers Squibb
Gliadel Wafer (carmustine in polifeprosan) - Eisai
Lomustine
Carboplatin
Cyclophosphamide
Etoposide
Irinotecan

4 Glioblastoma Pipeline

DCVax-L - Northwest Biotherapeutics
Rindopepimut (CDX-110) - Celldex Therapeutics
Avastin (bevacizumab)- Roche
ICT-107 - ImmunoCellular Therapeutics
Cotara- Peregrine Pharmaceuticals
Eir-060- EirGen Pharma
Heat Map of Safety and Efficacy and Competitor Matrix for Glioblastoma Multiforme Pipeline

5 Market forecasts

6 Deals and Strategic Consolidations

Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
Immatics Biotechnologies Enters into Agreement with Cancer Research UK
ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children's Hospital Medical Center
Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Appendix

For more information visit http://www.researchandmarkets.com/research/rp9tdm/glioblastoma

Research and Markets
Laura Wood, Senior Manager
[e-mail]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call [phone]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets